PE20090115A1 - Derivados de indol-2-il-piperazin-1-il-metanona - Google Patents

Derivados de indol-2-il-piperazin-1-il-metanona

Info

Publication number
PE20090115A1
PE20090115A1 PE2008000253A PE2008000253A PE20090115A1 PE 20090115 A1 PE20090115 A1 PE 20090115A1 PE 2008000253 A PE2008000253 A PE 2008000253A PE 2008000253 A PE2008000253 A PE 2008000253A PE 20090115 A1 PE20090115 A1 PE 20090115A1
Authority
PE
Peru
Prior art keywords
indol
piperazin
lower alkyl
methanone
iloxi
Prior art date
Application number
PE2008000253A
Other languages
English (en)
Inventor
Matthias Heinrich Nettekoven
Jean-Marc Plancher
Hans Richter
Olivier Roche
Sven Taylor
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090115A1 publication Critical patent/PE20090115A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE INDOL-2-IL-PIPERAZIN-1-IL-METANONA DE FORMULA (I), EN DONDE A ES C(O), S(O)2; R1 ES ALQUILO INFERIOR, ALCOXI INFERIOR, CICLOALQUILO, CICLOALQUILALQUILO INFERIOR, ENTRE OTROS; R2 ES H, ALQUILO INFERIOR, PIRIDILO, ENTRE OTROS; R3 ES H, HALOGENO O METILO; R4 ES UN GRUPO DE FORMULA (R4a) O (R4b), ENTRE OTROS. SON SELECCIONADOS [6-BROMO-5-(1-ISOPROPIL-PIPERIDIN-4-ILOXI)-1H-INDOL-2-IL]-[4-(PIPERIDINA-1-SULFONIL)- PIPERAZIN-1-IL]-METANONA, DIMETILAMIDA DEL ACIDO 4-[6-BROMO-5-(1-ISOPROPIL-PIPERIDIN-4-ILOXI)-1H-INDOL-2-CARBONIL]-PIPERAZINA-1-SULFONICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON MODULADORES DE RECEPTORES H3, SIENDO UTILES EN EL TRATAMIENTO DE LA OBESIDAD Y RELACIONADOS
PE2008000253A 2007-02-07 2008-02-05 Derivados de indol-2-il-piperazin-1-il-metanona PE20090115A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07101879 2007-02-07

Publications (1)

Publication Number Publication Date
PE20090115A1 true PE20090115A1 (es) 2009-02-13

Family

ID=39353037

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000253A PE20090115A1 (es) 2007-02-07 2008-02-05 Derivados de indol-2-il-piperazin-1-il-metanona

Country Status (13)

Country Link
US (1) US7507736B2 (es)
EP (1) EP2118089B1 (es)
JP (1) JP2010518043A (es)
CN (1) CN101611027A (es)
AR (1) AR065180A1 (es)
AT (1) ATE467626T1 (es)
CA (1) CA2676265A1 (es)
CL (1) CL2008000365A1 (es)
DE (1) DE602008001249D1 (es)
ES (1) ES2342235T3 (es)
PE (1) PE20090115A1 (es)
TW (1) TW200840577A (es)
WO (1) WO2008095821A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101316840B (zh) * 2005-11-30 2012-08-08 霍夫曼-拉罗奇有限公司 1,5-取代的吲哚-2-基酰胺衍生物
TW200823204A (en) * 2006-10-17 2008-06-01 Arena Pharm Inc Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine H3-receptor useful for the treatment of disorders related thereto
KR20100027231A (ko) * 2007-07-25 2010-03-10 에프. 호프만-라 로슈 아게 벤조퓨란- 및 벤조[ｂ]티오펜-2-카복실산 아마이드 유도체 및 이의 히스타민 3 수용체 조절제로서의 용도
WO2009097995A1 (de) * 2008-02-07 2009-08-13 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813144D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
CN105148896B (zh) * 2015-08-03 2017-09-22 贵州蓝天固废处置有限公司 一种废汞触媒中活性炭循环回收利用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000626D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
KR101093345B1 (ko) 2002-02-01 2011-12-14 아스트라제네카 아베 퀴나졸린 화합물
EP1620434B1 (en) * 2003-05-07 2011-03-09 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
US20040224952A1 (en) 2003-05-07 2004-11-11 Cowart Marlon D. Fused bicyclic-substituted amines as histamine-3 receptor ligands
NZ551663A (en) 2004-06-21 2009-09-25 Hoffmann La Roche Indole derivatives as histamine receptor antagonists
US20060069087A1 (en) 2004-09-27 2006-03-30 Pfizer Inc Histamine-3 receptor antagonists
DE602006014022D1 (de) 2005-11-30 2010-06-10 Hoffmann La Roche 5-substituierte indol-2-carbonsäureamidderivate
CN101316840B (zh) 2005-11-30 2012-08-08 霍夫曼-拉罗奇有限公司 1,5-取代的吲哚-2-基酰胺衍生物

Also Published As

Publication number Publication date
ATE467626T1 (de) 2010-05-15
ES2342235T3 (es) 2010-07-02
CN101611027A (zh) 2009-12-23
EP2118089B1 (en) 2010-05-12
CL2008000365A1 (es) 2008-08-08
WO2008095821A1 (en) 2008-08-14
DE602008001249D1 (de) 2010-06-24
CA2676265A1 (en) 2008-08-14
EP2118089A1 (en) 2009-11-18
JP2010518043A (ja) 2010-05-27
US20080188484A1 (en) 2008-08-07
TW200840577A (en) 2008-10-16
AR065180A1 (es) 2009-05-20
US7507736B2 (en) 2009-03-24

Similar Documents

Publication Publication Date Title
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20090115A1 (es) Derivados de indol-2-il-piperazin-1-il-metanona
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
PE20091035A1 (es) Derivados de 2-aminopirimidina
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
PE20140865A1 (es) Inhibidores de la tirosina-quinasa de bruton
PE20120321A1 (es) Indazoles sustituidos con oxazol como inhibidores de pi3-quinasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090622A1 (es) Nuevos derivados de bencimidazol sustituido
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20091324A1 (es) Compuestos espiro como antagonistas del receptor npy y5
AR049696A1 (es) Derivados de indol
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
PE20090482A1 (es) Derivados heterociclicos como antagonistas del receptor ccr2
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
ATE478856T1 (de) Spirobenzodioxole und deren verwendung als cb1- antagonisten
PE20060572A1 (es) Compuestos de benzoimidazolona como inhibidores de hsp90
PE20110703A1 (es) Acidos naftilaceticos
AR061656A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y procesos para la preparacion de la composicion y del compuesto
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet

Legal Events

Date Code Title Description
FD Application declared void or lapsed